Regencell Bioscience (NASDAQ:RGC) Trading Up 5.2% – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price traded up 5.2% during trading on Tuesday . The company traded as high as $24.84 and last traded at $24.70. 117,312 shares were traded during mid-day trading, a decline of 98% from the average session volume of 7,253,475 shares. The stock had previously closed at $23.48.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Monday, December 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, Regencell Bioscience has an average rating of “Sell”.

Regencell Bioscience Stock Performance

The company’s 50 day simple moving average is $15.70.

Hedge Funds Weigh In On Regencell Bioscience

Large investors have recently modified their holdings of the company. XTX Topco Ltd purchased a new stake in shares of Regencell Bioscience during the 3rd quarter worth about $598,000. Squarepoint Ops LLC purchased a new position in Regencell Bioscience in the second quarter valued at approximately $1,701,000. BNP Paribas Financial Markets acquired a new position in Regencell Bioscience during the second quarter valued at approximately $768,000. Geode Capital Management LLC grew its stake in Regencell Bioscience by 5,637.5% during the second quarter. Geode Capital Management LLC now owns 391,066 shares of the company’s stock worth $6,664,000 after buying an additional 384,250 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Regencell Bioscience in the second quarter worth $222,000. 0.13% of the stock is currently owned by hedge funds and other institutional investors.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.